Compare Merck & Co., Inc. (MRK) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs SiTime Corporation — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while SiTime Corporation trades at $600 (market cap $16.63B). The key difference: Merck & Co., Inc. is far larger — about 18.5× SiTime Corporation's market cap, and Merck & Co., Inc. pays a 2.73% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals.
| MRK | SITM | |
|---|---|---|
Market Cap | $307.25B | $16.63B |
Sector | Health | Technology |
52-Week High | $129.52 | $901.60 |
52-Week Low | $77.60 | $190.16 |
Enterprise Value | $350.66B | $15.84B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
SITM trades at $555.15, showing minimal daily movement with a 0.03% gain. The stock faces technical headwinds with a bearish moving average signal, though RSI levels suggest potential oversold conditions. Fundamentally, the company demonstrates strong revenue growth and consistent earnings beats, but operates at a net loss with negative margins. Recent developments include the completed acquisition of Renesas' timing business and strong AI-driven demand, with Q2 2026 results due August 5, 2026.
Analyst consensus remains strongly bullish with a $825 price target representing 49% upside potential. Key opportunities include accelerating AI infrastructure demand and strategic acquisitions, while risks center on continued profitability challenges and high valuation multiples. The company's growth trajectory appears promising, but investors should monitor the transition to sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
